ÂÜÀòÂÒÂ×

Nick Pelton has a diverse work experience spanning across multiple companies and roles. Nick began their career as an Analytical Method Development Technician at the Health Protection Agency in 2009. Nick then worked as a Project Analyst at Mice and Megahertz from January to August 2011.

In 2012, Nick joined Bio Products Laboratory Limited as a Downstream Production Technician, where they worked until May 2013. During this time, they gained hands-on experience in downstream production processes.

Nick's next position was as a Senior Biotechnologist at Oxford BioMedica from June 2013 to August 2016. Nick managed a team of six Biotechnologists and oversaw the manufacturing of Lentiviral vector batches for Novartis' CTL019 (Kymriah) program. Their responsibilities included scheduling manufacturing activities, ensuring procedure compliance, and implementing downstream processing methods.

From September 2016 to June 2019, Nick worked as an Advanced Therapy Production Scientist at Guy's and St Thomas' NHS Foundation Trust. Here, they applied their expertise in advanced therapy production and contributed to the development of novel therapies.

Their most recent position is as a Scientist at Quell Therapeutics, where they have held two roles. Nick joined the company in July 2019 as a Scientist - CMC Vector. In July 2021, they were promoted to Scientist II.

Throughout their career, Nick has consistently demonstrated their proficiency in the biotechnology field, contributing to various aspects of vector production and advanced therapy manufacturing.

Nick Pelton's education history includes obtaining a Bachelor of Science (BSc) degree in Biochemistry from the University of Southampton, starting in 2005 and ending in 2008. In 2017, they attended King's College London and earned an MSc in Stem Cells & Regenerative Therapies from Bench to Market. However, there is no information provided regarding the duration of their MSc program.